SB-1089 • 2026

Preventive Treatment Health Care Act.

Labor

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Richardson
Last action: 2026-06-04
Official status: Referred to Coms. on HEALTH and P. E. & R.
Effective date: Not listed

Plain English Breakdown

The bill summary does not provide details on how CHHSA will work with others to increase competition, lower prices, or fix shortages beyond creating GLP-1 generics.

Preventive Treatment Health Care Act

This act requires California to produce generic drugs, including a type called GLP-1, and mandates health plans for public employees to cover weight management programs that include nutritional advice and at least one FDA-approved GLP-1 drug.

What This Bill Does

Requires the California Health and Human Services Agency (CHHSA) to make partnerships to create generic versions of insulin and other drugs like GLP-1.
Mandates health plans for public employees to cover weight management programs starting in 2028 until 2032, including nutritional advice and at least one FDA-approved GLP-1 drug.

Who It Names or Affects

The California Health and Human Services Agency (CHHSA)
Public employees and annuitants in California

Terms To Know

GLP-1: A type of drug used to treat diabetes and obesity.
FDA: The United States Food and Drug Administration, which approves drugs for use in the U.S.

Limits and Unknowns

Does not specify what happens after January 1, 2032.
It is unclear how much this will cost or who will pay for it.

Bill History

2026-06-04 California Legislative Information
Referred to Coms. on HEALTH and P. E. & R.
2026-05-27 California Legislative Information
In Assembly. Read first time. Held at Desk.
2026-05-27 California Legislative Information
Read third time. Passed. (Ayes 39. Noes 0.) Ordered to the Assembly.
2026-05-18 California Legislative Information
Read second time. Ordered to third reading.
2026-05-14 California Legislative Information
Read second time and amended. Ordered to second reading.
2026-05-14 California Legislative Information
From committee: Do pass as amended. (Ayes 7. Noes 0.) (May 14).
2026-05-08 California Legislative Information
Set for hearing May 14.
2026-05-04 California Legislative Information
May 4 hearing: Placed on APPR. suspense file.
2026-04-28 California Legislative Information
Set for hearing May 4.
2026-04-23 California Legislative Information
Read second time and amended. Re-referred to Com. on APPR.
2026-04-22 California Legislative Information
From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 5. Noes 0. Page 4013.) (April 22).
2026-04-16 California Legislative Information
From committee: Do pass and re-refer to Com. on L., P.E. & R. (Ayes 10. Noes 0. Page 3901.) (April 15). Re-referred to Com. on L., P.E. & R.
2026-04-15 California Legislative Information
Set for hearing April 22 in L., P.E. & R. pending receipt.
2026-03-27 California Legislative Information
Set for hearing April 15.
2026-03-24 California Legislative Information
From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH.
2026-02-26 California Legislative Information
Referred to Coms. on HEALTH and L., P.E. & R.
2026-02-17 California Legislative Information
From printer. May be acted upon on or after March 16.
2026-02-13 California Legislative Information
Introduced. Read first time. To Com. on RLS. for assignment. To print.

Official Summary Text

SB 1089, as amended, Richardson.
Preventive Treatment Health Care Act.
(1) Existing law requires the California Health and Human Services Agency (CHHSA) to enter into partnerships resulting in the production of generic prescription drugs, including at least one form of insulin made available at production and dispensing costs, if one does not already exist in the market. Existing law additionally authorizes CHHSA to enter into partnerships to increase competition, lower prices, and address supply shortages for generic or brand name drugs to address emerging health concerns.
This bill, the Preventive Treatment Health Care Act, would specify that the above-described authorized partnerships include those for at least one glucagon-like peptide-1 (GLP-1) approved by the United States Food and Drug Administration (FDA).
(2) Existing
law authorizes the Board of Administration of the Public Employees’ Retirement System to contract with carriers to provide health benefit plans and contracts for employees and annuitants. Existing law sets forth specified coverage requirements for these health benefit plans and contracts.
Commencing January 1, 2028, until January 1, 2032, this bill would require a health benefit plan or contract offered to public employees and annuitants to offer coverage for chronic weight disease
management,
management or to treat obesity or overweight persons,
including nutritional information and at least one GLP-1 approved by the FDA.

Current Bill Text

Read the full stored bill text

Download Bill PDF